Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12711MR)

This product GTTS-WQ12711MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12711MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4548MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ15253MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ9440MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ4134MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ439MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ12150MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ15953MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ7581MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW